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Abstract
As the most important tool to provide high-level evidence-based medicine, re-
searchers can statistically summarize and combine data from multiple studies by
conducting meta-analysis. In meta-analysis, mean differences are frequently used
effect size measurements to deal with continuous data, such as the Cohen’s d statis-
tic (Cohen, 2013) and Hedges’ g statistic (Hedges, 1981) values. To calculate the
mean difference based effect sizes, the sample mean and standard deviation are two
essential summary measures. However, many of the clinical reports tend not to
directly record the sample mean and standard deviation. Instead, the sample size,
median, minimum and maximum values and/or the first and third quartiles are re-
ported. As a result, researchers have to transform the reported information to the
sample mean and standard deviation for further compute the effect size. Since most
of the popular transformation methods were developed upon the normality assump-
tion of the underlying data, it is necessary to perform a pre-test before transforming
the summary statistics. In this article, we had introduced test statistics for three
popular scenarios in meta-analysis. We suggests medical researchers to perform a
normality test of the selected studies before using them to conduct further analysis.
Moreover, we applied three different case studies to demonstrate the usage of the
newly proposed test statistics. The real data case studies indicate that the new test
statistics are easy to apply in practice and by following the recommended path to
conduct the meta-analysis, researchers can obtain more reliable conclusions.
Keywords: Meta-analysis, Median, Mid-range, Mid-quartile range, Test statistic,
Sample size
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1 Introduction
Meta-analysis is the most important tool to provide high-level evidence in evidence-based
medicine. By conducting meta-analysis, researchers can statistically summarize and com-
bine data from multiple studies with some pre-determined summary measure. In most
of the studies, mean difference is one of the frequently used effect size measurements for
continuous data. For example, Cohen’s d statistic (Cohen, 2013) and Hedges’ g statistic
(Hedges, 1981) are two of the most famous mean difference measurements. In order to
calculate the mean difference based effect sizes, the sample mean and standard deviation
are two essential summary measures. In practical research, most of the medical studies
provide the sample mean and standard deviation directly but, some of the clinical studies
tend to report the summary statistics such as the sample median, quartiles and extremas.
As a result, researchers had developed a few methods to transform the reported infor-
mation to the sample mean and standard deviation for further analysis. In particular,
Hozo et al. (2005) was the first to establish estimators for the sample mean and stan-
dard deviation. Wan et al. (2014) further improved Hozo et al.’s estimators of the sample
standard deviation and Luo et al. (2017) developed the optimal estimators of the sample
mean.
These estimation methods, especially the methods proposed by Wan et al. were widely
adopted in medical research area and had been frequently cited after published. In partic-
ular, Wan et al.’s methods have already gained 274 citations in Google Scholar. However,
among the current meta-analysis studies, researchers usually apply the estimation meth-
ods to all kind of reported data directly, without considering the symmetry of original
data. For instance, we consider an example with the data obtained from Hawkins et al.
(2017), a meta-analysis about the association between B-type natriuretic peptides (BNP)
and chronic obstructive pulmonary disease (COPD). Totally there were 51 studies in-
cluded in the meta-analysis and the authors discussed situations about stable disease
cases, exacerbation cases and comparison between these two phases of patients. For il-
lustration purpose, we only reported 7 studies that recorded information of both patients
and healthy individuals within stable disease phase in Table 1. In Hawkins et al. (2017),
the authors used the methods in Wan et al. (2014) to estimate the sample mean and
standard deviation. The authors claimed that they found most of the recorded data were
possibly not symmetric and they realized all the existing transformation methods were
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developed based on the symmetric assumption. For example for Study 5, the median BNP
level for the control group is 50 but the third quartile is just 51, which indicates that the
underlying data are more likely to be right skewed. In spite of this, the authors still con-
ducted the transformation and they believed the major error of the statistical results were
generated by the normality assumption of transformation methods. Although Luo et al.’s
methods of estimating the sample mean and Wan et al.’s standard deviation estimators
were proved to have very good performance for both symmetric and skewed data, the au-
thors in Hawkins et al. (2017) still had concern about the reliability of the transformation
methods. Under such circumstances, we believe it is essential to seek for a better solution
to help people further filter the studies before performing the meta-analysis.
Table 1: Summary of included studies
Index Study Sample size BNP Levels
1 Anderson et al. (2013)
Case 93 29±6
Control 93 26(20-32)
2 Gemici et al. (2008)
Case 17 21±16
Control 17 13±11
3 Boschetto et al. (2013)
Case 23 121(59-227)
Control 23 50(43-51)
4 Wang et al. (2013)
Case 80 245(196-336)
Control 80 101(56-150)
5 Beghe´ et al. (2013)
Case 70 115(50-364)
Control 70 50(43-51)
6 Bando et al. (1999)
Case 14 13±3
Control 14 7±1
7 Bozkanat et al. (2005)
Case 38 21±10
Control 38 9±3
· Observations are expressed as mean ± SD or median (interquartile range).
As a matter of fact, in both Wan et al. (2014) and Luo et al. (2017), the estimators
of the sample mean and standard deviation are proposed based on the assumption that
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Selected studies
Pre-test if data
is symmetric ?
Estimate the sample
mean using methods
of Luo et al. (2017)
Estimate the sample
standard deviation
using methods of
Wan et al. (2014)
Exclude this data
Compute the
effect size
Further analysis
and make decision
Yes
No
Figure 1: Recommended procedure of computing effect sizes for meta-analysis
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the underlying data is normally distributed. Therefore, if the original data is skewed or
very skewed, it might be inappropriate to treat this kind of data as normally distributed.
Furthermore, it is natural to consider that in clinical trial studies, when the underlying
data is not symmetric, reporting the sample median rather than the sample mean is
reasonable. In this case, when the original data is skewed, transforming the reported
information (such as the sample median, minimum and maximum values) to the sample
mean and standard deviation may lead to lack of accuracy in the follow-up analysis.
In view of the above situation, we propose some new test statistics to pre-test whether
the underlying data is normally distributed or not. If there is no significant evidence
to prove that the selected study is skewed, researchers may consider to transform the
reported information to the sample mean and standard deviation. Otherwise, we suggest
that researchers may consider to not to include the tested study when conducting meta-
analysis. In this case, we suggest when conducting meta-analysis, researchers can follow
the procedures as shown in the below flowchart.
Based on the above motivation, in this paper, we propose new test statistics for three
most frequently used scenarios in clinical trial reports as mentioned in both Wan et al.
(2014) and Luo et al. (2017), which may help researchers better choose the included stud-
ies for conducting meta-analysis. For the proposed test statistics for each scenario, we
conduct simulation studies to check whether the new test methods perform well in prac-
tice. We also apply a few real data examples to illustrate the usefulness of the new
test statistics. Eventually, we summarize our new test statistics and discuss some future
directions.
2 Motivation
To better illustrate the issue we mentioned in previous section, we choose five popular
skewed distributions as examples to show how skewed data may affect the medical decision.
Suppose we are computing the effect size for some paired experiments about a certain
disease. For the sake of consistency, we follow the notations as used in Luo et al. (2017):
using letters a, m, b to denote the sample minimum value, median and maximum value
for a study with size n, respectively.
In Table 2, let the log-normal distribution with location parameter µ = 0 and scale
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parameter σ = 1 for the disease cases, µ = 1, σ = 1 for the controls; the chi-square
distribution with degrees of freedom df = 3 for the disease cases, df = 4 for controls;
the exponential distribution with rate parameter λ = 1 for the disease cases, λ = 1.5 for
controls; the beta distribution with shape parameters α = 2 and β = 5 for the disease
cases, α = 2, β = 7 for controls; and the Weibull distribution with shape parameter
k = 1.5 and scale parameter λ = 1 for the disease cases, k = 3, λ = 1 for controls. These
distributions are used to generate the true sample mean, minimum (a), maximum (b) and
median (m). We then use the method in Luo et al. (2017) to estimate the sample mean
and use the method in Wan et al. (2014) to estimate the standard deviation for further
analysis. Eventually, we compute the effect size (Cohen’s d value) using the estimated
sample mean as well as the actual sample mean and make comparison. Note that for ease
of computation, we assume the sample sizes for both the disease cases and controls are
the same and the sample sizes for different distributions are arbitrarily chosen.
Table 2: Example of 5 skewed distributed data
Data
Distribution
Size
(Cases)
Size (Controls)
Summary statistics
(Cases)
Summary statistics
(Controls)
Log-normal 350 350 a = 0.03,m = 1.00, b = 28.11 a = 0.23,m = 2.52, b = 33.56
Chi-square 200 200 a = 0.06,m = 2.66, b = 9.60 a = 0.07,m = 3.72, b = 28.91
Exponential 150 150 a = 0.002,m = 0.67, b = 6.82 a = 0.003,m = 0.46, b = 4.07
Beta 300 300 a = 0.001,m = 0.26, b = 0.76 a = 0.005,m = 0.21, b = 0.64
Weibull 400 400 a = 0.01,m = 0.85, b = 2.99 a = 0.16,m = 0.86, b = 1.93
From Tables 2 and 3, we clearly find that if the underlying distribution is very skewed,
estimating the sample mean and standard deviation using the summary statistics may lead
to an incorrect conclusion. In particular, for the log-normal distribution and chi-square
distribution in Table 3, the effect size computed by the actual sample mean is within the
median effect level but the effect size computed by the estimated sample mean is in the low
effect level. As a result, testing the normality of the underlying data before estimating
the sample mean and standard deviation is of crucial importance. The normality test
may help researchers to filter out the skewed data and further reduce the estimation error
when computing the effect sizes. Motivated by this circumstance, we will propose some
new test statistics for three frequently used scenarios in Section 3. The simulation results
Table 3: Effect sizes comparison of 5 skewed distributed data
Data
Distribution
(Cases) True
mean (SD)
(Controls) True
mean (SD)
(Cases)
Estimated
Mean (SD)
(Controls)
Estimated
Mean (SD)
Effect Size
(use estimated
mean)
Effect Size
(use true
mean)
Log-normal 1.72 (2.70) 4.05 (4.64) 1.61 (4.82) 3.20 (5.72) 0.30 0.61
Chi-square 3.08 (2.17) 4.71 (3.82) 2.81 (1.74) 4.48 (5.27) 0.42 0.53
Exponential 1.07 (1.13) 0.70 (0.73) 0.90 (1.29) 0.59 (0.12) -0.34 -0.39
Beta 0.28 (0.16) 0.23 (0.12) 0.27 (0.13) 0.22 (0.11) -0.42 -0.35
Weibull 0.93 (0.58) 0.89 (0.33) 0.88 (0.50) 0.87 (0.30) -0.02 -0.08
and the real data case studies in the later sections indicate the good performance of the
new test methods.
3 Test methods
For the sake of consistency, we follow the same notations as those in Luo et al. (2017).
Let n be the sample size and denote the 5-number summary for the data as
a = the minimum value,
q1 = the first quartile,
m = the median,
q3 = the third quartile,
b = the maximum value.
In this work, we consider the three most frequently occurred scenarios in clinic trial
reports:
S1 = {a,m, b;n},
S2 = {q1, m, q3;n},
S3 = {a, q1, m, q3, b;n}.
According to (Triola, 2009), we refer to (b− a) as the range, (a+ b)/2 as the mid-range,
(q3 − q1) as the interquartile range, and (q1 + q3)/2 as the mid-quartile range. Note that
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according to Wan et al. (2014) and Luo et al. (2017), the mid-range and the mid-quartile
range are used to estimate the sample mean, while the range and the interquartile range
are used to estimate the standard deviation.
For the following sections, our general assumption is letting X1, X2, . . . , Xn be a ran-
dom sample of size n from the normal distribution N(µ, σ2), and X(1) ≤ X(2) ≤ · · · ≤ X(n)
be the ordered statistics of the sample. According to Chen (2004), we use X([np]) to denote
the sample pth quantile, where p ∈ (0, 1) and [np] represents the integer part of np. With
the above notations, we have a = X(1), q1 = X([0.25n]), m = X([0.5n]), q3 = X([0.75n]), and
b = X(n).
For convenience, let also Xi = µ+σZi, or equivalently, X(i) = µ+σZ(i) for i = 1, . . . , n.
Then Z1, Z2, . . . , Zn follows the standard normal distribution N(0, 1), and Z(1) ≤ Z(2) ≤
· · · ≤ Z(n) are the ordered statistics of the sample {Z1, . . . , Zn}.
3.1 Hypothesis test for S1 = {a,m, b;n}
Note that the proposed estimators of the sample mean in Luo et al. (2017) and the estima-
tors of the standard deviation in Wan et al. (2014) are developed based on the normality
assumption. To ensure the accuracy of the estimation results, it is natural to test whether
the population data are normally distributed or not. That is, if the data does not pass the
test, we may conclude the underlying data is not normally distributed and hence it is not
appropriate to be used in the sample mean and standard deviation estimation. Therefore,
the hypothesis we proposed for this scenario is:
H0 : The data follow a normal distribution,
H1 : The data do not follow a normal distribution.
As the most important property of normal distribution is the symmetry property, we
will use it to identify the normality of the underlying distribution. Under the situation of
scenario S1, only the sample median and extremes are reported. Therefore, it is reasonable
to consider comparing the distances between the sample median to the minimum as well
as it to the maximum, i.e. computing the value of (b−m)− (m− a). If the difference is
very close to zero, we may conclude that the original data is normally distributed. Based
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on the above hypothesis, we introduce the following test statistic, T :
T =
a+ b− 2m
SE(a+ b− 2m) . (1)
By Theorem 1 in Appendix B, the simplified test statistic under the null hypothesis H0
is
T0 =
a+ b− 2m
σ
√
pi2
6 log(n)
+ pi
n
. (2)
Note that σ is unknown and need to be estimated. Based on Wan et al. (2014), the
estimation of the sample standard deviation for scenario S1 is
σˆ ≈ b− a
2Φ−1
(
n−0.375
n+0.25
) . (3)
Plugging (3) into (2), we can easily get the modified test statistic for this scenario:
T1 =
τ(n) (a+ b− 2m)
b− a , (4)
where τ(n) = 2Φ−1
(
n−0.375
n+0.25
)/√
pi2
6 log(n)
+ pi
n
is the coefficient function related to the sample
size n.
Based on the above test statistic, if the observed T1 is within the interval [−1.96, 1.96],
we accept the null hypothesis and conclude that the underlying data is normally dis-
tributed. Thus, we can continue to conduct the data transformation, which is to estimate
the sample mean and standard deviation from the 5-number summary statistics. Other-
wise, if the null hypothesis is rejected, we suggest researchers not to include the tested
data when proceeding meta-analysis.
3.2 Hypothesis test for S2 = {q1, m, q3;n}
Similar to the previous section, the hypothesis is defined as:
H0 : The data follow a normal distribution,
H1 : The data do not follow a normal distribution.
Under the case of scenario S2, only the sample quartiles are provided. Based on the
symmetry property of the normal distribution, in population aspect, the distance between
the first quartile and the median is equal to that from the median to the third quartile. As
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a result, we introduce a test statistic which compares these two distances, i.e. computing
the value of (q3 −m)− (m− q1). By the above setting, the test statistic for this scenario
is:
T =
q1 + q3 − 2m
SE(q1 + q3 − 2m) . (5)
By Theorem 2 in Appendix B, the simplified test statistic under the null hypothesis H0
is
T0 =
√
n (q1 + q3 − 2m)
1.83σ
. (6)
Similar to Section 2.1, σ is unknown and by Wan et al. (2014), the estimation of the
sample standard deviation for scenario S2 is
σˆ ≈ q3 − q1
2Φ−1
(
0.75n−0.125
n+0.25
) . (7)
Plugging (7) into (6), we can easily obtain the updated test statistic for this scenario:
T2 =
ϕ(n) (q1 + q3 − 2m)
q3 − q1 , (8)
where ϕ(n) = 1.09
√
nΦ−1
(
0.75n−0.125
n+0.25
)
is the coefficient function related to the sample size
n.
Similarly, if the observed T2 is within the interval [−1.96, 1.96], we accept the null
hypothesis and regard the underlying data as applicable to perform the estimation of
the sample mean and standard deviation. Otherwise, we suggest that researchers should
remove the tested data from further analysis procedure.
3.3 Test statistic for S3 = {a, q1, m, q3, b;n}
In this section, we discuss the case of all 5-number summary statistics are provided.
Similar to the previous two subsections, the hypothesis is defined as:
H0 : The data follow a normal distribution,
H1 : The data do not follow a normal distribution.
Recall that in the previous subsections, the symmetry property of normal distribution is
used to test the normality of underlying data. In Section 2.1, the test statistic is built
by comparing the difference in distances between the sample extremes to the median, i.e.
computing (b−m) and (m−a), respectively. In Section 2.2, the value of (q3−m)−(m−q1)
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is computed to measure the difference in distances between the sample quartiles to the
median. Hence, taking both previous ideas into account, we introduce the following test
statistic:
T =
a+ b+ q1 + q3 − 4m
SE(a + b+ q1 + q3 − 4m) . (9)
By Theorem 3 in Appendix B, the simplified test statistic under the null hypothesis is
T0 =
a+ b+ q1 + q3 − 4m
σ
√
pi2
6 log(n)
+ 10.14
n
, (10)
where σ is unknown. Therefore, the next task is to determine an estimator of the sample
standard deviation σ.
Following the similar idea as in Wan et al. (2014), by Lemma 1, we have E(b − a +
q3 − q1) = 2σ
[
E(Zn) + E(Z([0.75n]))
]
, which leads to the estimator σˆ ≈ (b − a + q3 −
q1)/
(
2E(Z(n)) + 2E(Z([0.75n]))
)
. According to Blom’s method of approximating E(Zi)
(Blom, 1958), the estimator of the sample standard deviation is defined as
σˆ ≈ b− a+ q3 − q1
2Φ−1
(
n−0.375
n+0.25
)
+ 2Φ−1
(
0.75n−0.125
n+0.25
) . (11)
Consequently, plugging (11) into (10), the updated test statistic T3 has the following
expression:
T3 =
κ(n)(a+ b+ q1 + q3 − 4m)
b− a+ q3 − q1 , (12)
where κ(n) =
[
2Φ−1
(
n−0.375
n+0.25
)
+ 2Φ−1
(
0.75n−0.125
n+0.25
)]/√
pi2
6 log(n)
+ 10.5
n
is the coefficient func-
tion related to the sample size n.
Based on the above definition, if the observed T3 is within the interval [−1.96, 1.96],
we accept the null hypothesis. Otherwise, the null hypothesis is rejected and we suggest
researchers not to include the tested data into meta-analysis.
4 Simulation studies
In this section, we conduct some simulation studies to evaluate the performance of the
test statistics in Section 2. The type I error and the statistical power will be computed.
To compute the statistical power of test statistics (4) and (8), we choose the following
skewed distributions as the alternative distribution: the standard log-normal distribution
with µ = 0, σ = 1; the standard exponential distribution with λ = 1; the beta distribution
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with shape parameters α = 1, β = 5; the Chi-square distribution with degree of freedom
df = 1 and the Weibull distribution with scale parameter λ = 1, shape parameter k = 2.
The simulation results indicate that all three test statistics can provide an acceptable
statistical power, as well as the type I error under control.
4.1 Simulation study for S1
Figure 2 shows the type I error of test statistic T1 in scenario S1 (Eq. (4)). Since
in practical research, the sample size n rarely drop below 30, we tend to focus on the
situation when n is large. Hence, although the type I error of T1 is not very close to
0.05 for small sample sizes, we consider it acceptable because the type I error is able
to maintain a value around 0.05 as n increases to 200 or larger. Figure 3 reports the
statistical power of test statistic T1. The simulation studies were conducted by assuming
the alternative distribution is not normal distribution. It is obvious that for all the five
skewed distributions, the statistical power increase to 1 rapidly (mostly increase to 1 before
n reaches 100). Consequently, with the type I error very close to 0.05 and a statistical
power close to 1, we consider that test statistic T1 may have impressive performance in
practical application and we will conduct a real data analysis to evaluate its performance
in the next section.
4.2 Simulation study for S2
Similar to section 3.1, Figure 4 shows the type I error of test statistic T2 in scenario S2 (Eq.
(8)). It is evident that the type I error is able to maintain a value around 0.05 especially
when the sample size n increases to more than 200. Figure 5 reports the statistical power
of test statistic T2 when the alternative distributions are skewed distributions. Compare
to section 3.1, the statistical power of test statistic T2 increases to 1 in a slower motion, it
reaches 1 only when the sample size n is larger than 400. However, since in practice, most
of the studies have large sample sizes, it is acceptable that test statistic T2 may provide
a statistical power that reaches 1 in a slightly slower speed. Also, as all the value of type
I error is around 0.05, we consider test statistic T2 may have a very good performance in
real-life application. In the next section, we will conduct real data analysis to evaluate
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Figure 2: Type I error for scenario S1.
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Figure 3: The statistical power for scenario S1.
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the performance of T2.
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Figure 4: Type I error for scenario S2.
4.3 Simulation study for S3
In this section, Figure 6 shows the type I error of test statistic T3 in scenario S3 (Eq.
(12)). In Figure 6, it is obvious that the type I error of T3 drop within the range of [-
0.045,0.055] and most of the points are very close to 0.05. Figure 7 reports the statistical
power of test statistic T3 with skewed alternative distributions. Similar to scenario S1,
the statistical power of T3 reaches toward 1 rapidly. Therefore, with a type I error around
0.05 and statistical power close to 1, we expect that T3 would have very good performance
in practice.
15
0 200 400 600 800 1000
0.
0
0.
4
0.
8
Alternative is standard log−normal distribution
n
St
at
ist
ica
l p
ow
e
r
0 200 400 600 800 1000
0.
0
0.
4
0.
8
Alternative is standard exponential distribution
n
0 200 400 600 800 1000
0.
0
0.
4
0.
8
Alternative is beta(1,5)
n
St
at
ist
ica
l p
ow
e
r
0 200 400 600 800 1000
0.
0
0.
4
0.
8
Alternative is Chi−square distribution with df=1
n
0 200 400 600 800 1000
0.
0
0.
4
0.
8
Alternative is weibull(2,1)
n
St
at
ist
ica
l p
ow
e
r
Figure 5: The statistical power for scenario S2.
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Figure 6: Type I error for scenario S3.
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Figure 7: The statistical power for scenario S3.
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5 Real data analysis
In this section, we tend to apply 2 real data analysis as examples to demonstrate the
usage of our proposed test statistics. The first case is about investigating the association
between asthma and leptin and adiponectin serum levels, respectively (Zhang et al., 2017).
The second case is to identify the effects of statin therapy on four indicators of plasma
lipid concentrations in HIV-infected patients (Banach et al., 2016). In both cases, some
data are recorded as the sample median and interquartile ranges, or median with the
sample extremum. In this section, test statistics T1 (4) and T2 (8) are used to conduct
the symmetry test of underlying data.
5.1 Case study of investigating the association of asthma diag-
nosis with leptin and adiponectin
The first data obtained from a meta-analysis about the effects of leptin and adiponectin
serum levels on the diagnosis of asthma (Zhang et al., 2017). The article is published
on the Journal of Investigative Medicine (JIM), one of the BMJ journals. It includes
13 studies and all the analysis is divided into 2 parts, one focus on leptin serum level
and the other focus on adiponectin serum level. For leptin serum level, 5 of the studies
report the sample median and interquartile range (satisfies scenario S2), 1 reports median,
minimum and maximum values (satisfies scenario S1). For adiponectin serum level, two of
the studies report the sample median and interquartile range. Hence, in this section, test
statistics T1 and T2 will be applied to evaluate whether the underlying data is symmetry
and can be further used to estimate the sample mean and standard deviation.
5.1.1 Data description
The reported information of the 13 studies in Zhang et al. (2017) are displayed in the
following Table 4. There are 12 studies that record the values of leptin serum level and
11 studies that record the values of adiponectin serum level. Since for both leptin and
adiponectin serum levels, some of the selected studies only provide summary measure-
ments (the sample median, interquartile range or extremum), it is essential to estimate
the sample mean and standard deviation (SD) from recorded information. However, all
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the existing sample mean and SD estimation methods are developed based on normality
assumption. As a result, before conducting the transformation, we will apply the symme-
try test as proposed in Section 2 to check whether the selected studies are reasonable to
be transformed.
5.1.2 Results of symmetry test and meta-analysis
The results of the symmetry tests are recorded in Table 5. Note that test statistic T1
is applied on study Cobanoglu et al. (2013) as it reports the sample median and ex-
tremum, test statistic T2 is applied to studies da Silva et al. (2012), Giouleka et al. (2011),
Leivo-Korpela et al. (2011), Kim et al. (2008) and Guler et al. (2004). To further proceed
meta-analysis, it is more reliable to only transform the studies with symmetric data, to
the sample mean and standard deviation via methods proposed by Luo et al. (2017) and
Wan et al. (2014). Thus, if the studies in Table 5 have p-value greater than 0.05 on both
asthma samples and healthy samples, these studies can be used to estimate the sample
mean and standard deviation. Note also that in Kim et al. (2008), patients were divided
into three groups: obese asthma, non-obese asthma and healthy individuals. In this case,
only when the p-values of all these three groups are greater than 0.05, we would compute
the sample mean and standard deviation for Kim et al. (2008) and further combine the
information of the first two groups.
It is obvious that for leptin serum level, all the studies, except for study da Silva et al.
(2012), have p-values less than 0.05 on either asthma samples or healthy samples. That
is, these 5 studies (Cobanoglu et al. (2013),Giouleka et al. (2011), Leivo-Korpela et al.
(2011), Kim et al. (2008) and Guler et al. (2004)) is not suitable to further conduct the
sample mean and standard deviation estimation. We suggest to exclude these five studies
from the meta-analysis of investigating the association between leptin serum level and
asthma.
Note that in studies Yuksel et al. (2012) and Kim et al. (2008), asthma patients were
separated into two different levels. Therefore, before computing the standardized mean
difference (SMD, i.e. the Cohen’s d value (Cohen, 2013)) as the effect size for these two
studies, we need to combine the information of those two levels of asthma as one. Note also
that since there are 5 studies did not pass the symmetry test, we excluded those studies in
the meta-analysis. As a result, we have the following forest plots for leptin and adiponectin
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Table 4: Summary of included studies in Zhang et al. (2017)
Study Type of asthma Sample size Leptin Adiponection
Hayashikawa et al. (2015)
Asthma 23 NS 13.47±9.08
Healthy 68 NS 14.04±8.82
Haidari et al. (2014)
Asthma 47 1.41±0.50 6.68±2.07
Healthy 47 0.59±0.19 7.55±2.10
Sood et al. (2014)
Asthma 44 34032.8±27597.8 4180.6±2671.1
Healthy 44 33263.4±27874.9 3987.4±3106.0
Cobanoglu et al. (2013)
Asthma 23 5.3[0.4-27.4] NS
Healthy 51 8.8[0.3-31.3] NS
Tsaroucha et al. (2013)
Asthma 32 24.8±14.8 13.5±9.2
Healthy 22 13.7±10.0 10.1±6.4
Yuksel et al. (2012)
Obese asthma 40 11.8±7.9 12586.2±3724.1
Non-obese asthma 51 5.3±6.8 18089.3±6452.3
Healthy 20 2.1±2.4 20297.5±3680.7
Sideleva et al. (2012)
Asthma 11 0.3051±0.047 0.3471±0.037
Healthy 15 0.1256±0.016 0.8666±0.134
da Silva et al. (2012)
Asthma 26 38(30-60) 4.5(3.5-8.5)
Healthy 50 39(25-50) 4(3-7.8)
Giouleka et al. (2011)
Asthma 100 9.6(7.6-16.25) 6.2(5.4-7.3)
Healthy 60 7.2(4.6-10.3) 8.2(5.8-13.5)
Leivo-Korpela et al. (2011)
Asthma 35 0.5(0.5-1.1) 165±9.5
Healthy 32 0.6(0.4-0.8) 176±13
Jang et al. (2009)
Asthma 60 2.31±0.04 1.90±0.17
Healthy 30 2.22±0.06 1.95±0.04
Kim et al. (2008)
Atopic asthma 149 2.27(0.65-5.03) 7.60±3.84
Non-atopic asthma 37 2.22(0.96-3.29) 8.10±4.73
Healthy 54 2.10(0.71-4.49) 7.32±4.19
Guler et al. (2004)
Asthma 102 3.53(2.06-7.24) NS
Control 33 2.26(1.26-4.71) NS
· Observations are expressed as mean ± SD, median (interquartile range) or median [minimum-maximum].
· NS indicates the information is not specified in the original study.
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Table 5: Results of normality test on reported data from Zhang et al. (2017)
Study Type of asthma
Sample
size
Leptin Adiponection
Test
statistic
p-value
Test
statistic
p-value
Cobanoglu et al. (2013)
Asthma 23 3.022 0.003 NS NS
Healthy 51 2.935 0.003 NS NS
da Silva et al. (2012)
Asthma 26 1.653 0.098 2.126 0.034
Healthy 50 -0.606 0.545 2.945 0.003
Giouleka et al. (2011)
Asthma 100 3.895 < 0.001 1.144 0.253
Healthy 60 0.488 0.626 2.093 0.036
Leivo-Korpela et al. (2011)
Asthma 35 4.171 < 0.001 NS NS
Healthy 32 2.205×10−15 1 NS NS
Kim et al. (2008)
Atopic asthma 149 2.313 0.021 NS NS
Non-atopic asthma 37 -0.351 0.726 NS NS
Healthy 54 1.391 0.164 NS NS
Guler et al. (2004)
Asthma 102 3.189 0.001 NS NS
Control 33 1.697 0.090 NS NS
· p-value< 0.05 indicates the underlying data is not symmetric.
· NS indicates the reported data do not need to conduct the symmetry test.
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Study
Random effects model
Heterogeneity: I2 = 93%, τ2 = 1.039, χ6
2
 = 89.76 (p < 0.01)
Haidari et al. (2014)
Sood et al. (2014)
Tsaroucha et al. (2013)
Yuksel et al. (2012)
Sideleva et al. (2012)
da Silva et al. (2012)
Jang et al. (2009)
Total
311
 47
 44
 32
 91
 11
 26
 60
Mean
    1.410
34032.800
   24.800
    8.157
    0.305
   43.005
    2.310
SD
    0.500
27597.800
   14.800
    7.262
    0.047
   23.530
    0.040
Asthma
Total
228
 47
 44
 22
 20
 15
 50
 30
Mean
    0.590
33263.400
   13.700
    2.100
    0.126
   37.938
    2.220
SD
    0.190
27874.900
   10.000
    2.400
    0.016
   19.083
    0.060
Healthy
−6 −4 −2 0 2 4 6
Standardised Mean
Difference SMD
1.43
2.17
0.03
0.85
0.91
5.47
0.24
1.89
95%−CI
[ 0.63; 2.23]
[ 1.66; 2.68]
[−0.39; 0.45]
[ 0.28; 1.41]
[ 0.41; 1.41]
[ 3.79; 7.15]
[−0.23; 0.72]
[ 1.38; 2.41]
Weight
100.0%
15.1%
15.4%
14.9%
15.1%
9.4%
15.2%
15.0%
Leptin: Statistics of each studies
(a) Leptin level
Study
Random effects model
Heterogeneity: I2 = 87%, τ2 = 0.386, χ8
2
 = 63.71 (p < 0.01)
Hayashikawa et al. (2015)
Haidari et al. (2014)
Sood et al. (2014)
Tsaroucha et al. (2013)
Yuksel et al. (2012)
Sideleva et al. (2012)
Leivo−Korpela et al. (2011)
Jang et al. (2009)
Kim et al. (2008)
Total
529
 23
 47
 44
 32
 91
 11
 35
 60
186
Mean
   13.470
    6.680
 4180.600
   13.500
15670.355
    0.347
  165.000
    1.900
    7.699
SD
   9.080
   2.070
2671.100
   9.200
5398.041
   0.037
   9.500
   0.170
   4.019
Asthma
Total
332
 68
 47
 44
 22
 20
 15
 32
 30
 54
Mean
   14.040
    7.550
 3987.400
   10.100
20297.500
    0.867
  176.000
    1.950
    7.320
SD
   8.820
   2.100
3106.000
   6.400
3680.700
   0.134
  13.000
   0.040
   4.190
Healthy
−6 −4 −2 0 2 4 6
Standardised Mean
Difference SMD
−0.50
−0.06
−0.42
0.07
0.42
−0.90
−4.95
−0.97
−0.35
0.09
95%−CI
[−0.95; −0.06]
[−0.54;  0.41]
[−0.83; −0.01]
[−0.35;  0.48]
[−0.13;  0.96]
[−1.40; −0.40]
[−6.50; −3.39]
[−1.48; −0.47]
[−0.80;  0.09]
[−0.21;  0.40]
Weight
100.0%
11.7%
12.1%
12.1%
11.2%
11.6%
5.1%
11.5%
11.9%
12.7%
Adiponectin: Statistics of each studies
(b) Adiponectin level
Figure 8: Forest plots for association between asthma versus leptin (8(a)) and adiponectin
levels (8(b)), respectively.
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levels. During computation, we used Luo et al. (2017)’s methods to estimate the sample
mean value and Wan et al. (2014)’s methods to estimate the standard deviations for
studies that only provided median and interquartile range or extremum. Based on Figure
8, there is extreme heterogeneity among the studies for both leptin and adiponectin levels
(Q = 89.76, I2 = 93%, p < 0.01 for leptin; Q = 63.71, I2 = 87%, p < 0.01 for adiponectin).
The overall results indicate that patients with asthma have significant higher levels of
leptin than healthy individuals (pooled standardized mean difference (SMD)= 1.43, with
95% CI from 0.63 to 2.23), and lower levels of adiponectin than healthy individuals (pooled
SMD= −0.50, with 95% CI from -0.95 to -0.06). Since this section is aimed to provide a
demonstration of how to use the proposed test statistics before conducting meta-analysis,
we would not further proceed the sensitivity analysis and the publication bias analysis.
The pooled conclusion is similar to Zhang et al. (2017). However, in the original
article, the authors did not conduct the symmetry test and they used Hozo et al.’s
methods(Hozo et al., 2005) to estimate the sample means and standard deviations. As
we had mention in introduction section, blindly estimate the sample mean and standard
deviation before testing the symmetry of underlying data may yield an inaccurate con-
clusion. Therefore, we suggest researchers to follow the procedure in Figure 1: conduct
symmetry test for selected studies, exclude studies that may have skewed underlying data
and then compute the individual and pooled effect sizes.
5.2 Case study of investigating the effects of statin therapy on
plasma lipid concentrations in HIV-infected patients
The second data is a meta-analysis to investigate the effects of statin therapy on plasma
lipid concentrations in HIV-infected patients (Banach et al., 2016). In this article, meta-
analysis contains 12 randomized control trials (RCT) with 697 participants. The reported
data included 5 types of cholesterol level that may influence plasma concentration: low
density lipoprotein cholesterol (LDL-C), total cholesterol, high density lipoprotein choles-
terol (HDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and triglycerides.
Note that in Banach et al. (2016), only two studies reports data of non-HDL-C and both
these two studies provided the sample mean and standard deviation. Hence in the follow-
ing discussion, we will remove variable non-HDL-C and focus on the other four types of
cholesterol level.
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5.2.1 Data description
The data of included studies are displayed in the following Table 6. For each type of
cholesterol level, data are reported either as the sample mean with standard deviation,
or as median with interquartile range. In this case, the test statistic T2 will be used to
conduct the symmetry test of the underlying data. Similar to the previous case study,
selected studies that have p-value greater than 0.05 are recommended to further proceed
the sample mean and standard deviation estimation. Otherwise, we regard that there is
evidence to conclude the underlying data of selected studies are not symmetric and hence,
we suggest researchers to remove those studies from the meta-analysis in order to obtain
more precise conclusion.
5.2.2 Results of symmetry test and meta-analysis
The test results are reported in Table 7. For total cholesterol level, both case samples
and control samples in study Ganesan et al. (2011) have p-value less than 0.05, i.e. there
is significant evidence to reject the symmetry null hypothesis for this study. For LDL-C,
the control samples in study Montoya et al. (2012) has p-value less than 0.05. For HDL-
C, both case samples and control samples in study Hu¨rlimann et al. (2006) have small
p-values (p = 0.024) and for triglycerides, all the studies have non-significant test results.
Similar to Section 4.1.2, after removing the studies with significant test results (i.e.
underlying data is more likely to be skewed), we obtain the following four forest plots
of effects of statin therapy on total cholesterol, LDL-C, HDL-C and triglycerides levels
in HIV-infected patients, respectively. Likewise, we only provide overall results in this
section due to demonstration purpose and will not further proceed sensitivity analysis
and publication bias analysis. The pooled results showed that there was very high het-
erogeneity among studies for total cholesterol level (Q = 40.01, I2 = 85% and p < 0.01)
and nearly no heterogeneity among studies for the other three plasma concentration levels
(I2 = 0% and p > 0.05). The overall effect sizes imply that by using statin therapy, HIV-
infected patients may have moderate growth in total cholesterol level (SMD= 0.43 with
95% CI from -0.32 to 1.17), slight growth in HDL-C and triglycerides levels (SMD= 0.04
with 95% CI from -0.17 to 0.25 for HDL-C; SMD= 0.01 with 95% CI from -0.23 to 0.26 for
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Table 6: Summary of included studies in Banach et al. (2016)
Study
Sample
size
Total
Cholesterol
(mmol/L)
LDL-C
(mmol/L)
HDL-C
(mmol/L)
Triglycerides
(mmol/L)
Bonnet et al. (2007)
Case 12 6.1(5.8-6.3) 4.1(3.7-4.6) 0.9(0.8-1.1) 2.0(1.1-3.3)
Control 9 6.4(6.1-7.7) 3.9(3.7-4.8) 1.0(0.8-1.1) 3.2(2.1-4.4)
Calmy et al. (2010)
Case 10 5.6(4.5-6.4) 2.8(2.4-3.3) 1.0(0.9-1.3) 3.9(2.0-6.2)
Control 12 5.6(4.6-6.2) 3.5(2.5-4.1) 1.1(0.81-1.2) 2.3(1.5-3.5)
Eckard et al. (2014)
Case 67 NS 2.48(1.96-2.77) NS NS
Control 69 NS 2.50(1.99-3.13) NS NS
Funderburg et al. (2015)
Case 72 NS NS 1.21(0.98-1.49) NS
Control 75 NS NS 1.19(0.96-1.47) NS
Ganesan et al. (2011)
Case 22 4.34(3.72-4.45) 2.50(2.25-2.82) NS NS
Control 22 4.34(3.72-4.45) 2.50(2.25-2.82) NS NS
Hu¨rlimann et al. (2006)
Case 29 6.4(6.0-7.4) 3.7(2.8-4.2) 1.2(1.1-1.6) 3.0(2.1-4.0)
Control 29 6.4(6.0-7.4) 3.7(2.8-4.2) 1.2(1.1-1.6) 3.0(2.1-4.0)
Lo et al. (2015)
Case 17 5.14±0.98 3.20±0.95 1.34±0.50 1.36(1.10-2.31)
Control 20 4.97±0.70 3.23±0.83 1.31±0.39 1.28(1.04-1.53)
Stein et al. (2004)
Case 20 5.58±0.40 3.47±0.32 0.94±0.07 3.78±0.67
Control 20 5.58±0.40 3.47±0.32 0.94±0.07 3.78±0.67
Nakanjako et al. (2015)
Case 15 NS 3.1(2.2-4.9) 1.7(1.6-1.8) 1.6(1.1-2.4)
Control 15 NS 4.9(2.4-6.7) 1.7(1.5-2.0) 2.0(1.4-3.2)
Montoya et al. (2012)
Case 51 NS 2.63(2.20-3.28) NS NS
Control 53 NS 2.53(2.30-3.10) NS NS
Moyle et al. (2001)
Case 14 7.5(6.7-8.3) 4.65(4.1-5.2) 0.94(0.79-1.08) 3.96(2.84-6.52)
Control 13 7.4(6.8-7.9) 4.68(3.89-5.47) 0.87(0.72-1.02) 4.06(2.20-5.97)
Mallon et al. (2006)
Case 14 7.6±1.7 NS 1.1±0.4 3.8±4.1
Control 17 7.6±1.4 NS 1.1±0.4 4.9±7.8
· Observations are expressed as mean ± SD or median (interquartile range).
· NS indicates the information is not specified in the original study.
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Table 7: Results of normality test on reported data from Banach et al. (2016)
Study
Sample
size
Total
Cholesterol
LDL-C HDL-C Triglycerides
Bonnet et al. (2007)
Case 12 -0.450(0.653) 0.250(0.802) 0.750(0.453) 0.409(0.682)
Control 9 1.168(0.243) 1.190(0.234) -0.623(0.533) 0.081(0.935)
Calmy et al. (2010)
Case 10 -0.316(0.752) 0.223(0.824) 1.002(0.316) 0.191(0.849)
Control 12 -0.563(0.574) -0.563(0.574) -1.097(0.273) 0.450(0.653)
Eckard et al. (2014)
Case 67 NS -1.672(0.095) NS NS
Control 69 NS 0.629(0.529) NS NS
Funderburg et al. (2015)
Case 72 NS NS 0.599(0.549) NS
Control 75 NS NS 0.612(0.540) NS
Ganesan et al. (2011)
Case 22 -2.254(0.024) 0.396(0.692) NS NS
Control 22 -2.254(0.024) 0.396(0.692) NS NS
Hu¨rlimann et al. (2006)
Case 29 1.613(0.107) -1.075(0.282) 2.258(0.024) 0.198(0.843)
Control 29 1.613(0.107) -1.075(0.282) 2.258(0.024) 0.198(0.843)
Lo et al. (2015)
Case 17 NS NS NS 1.585(0.113)
Control 20 NS NS NS 0.062(0.950)
Stein et al. (2004)
Case 20 NS NS NS NS
Control 20 NS NS NS NS
Nakanjako et al. (2015)
Case 15 NS 0.860(0.390) 5.73×10−15(1.000) 0.596(0.551)
Control 15 NS -0.420(0.674) 0.516(0.606) 0.860(0.390)
Montoya et al. (2012)
Case 51 NS 1.039(0.299) NS NS
Control 53 NS 2.213(0.027) NS NS
Moyle et al. (2001)
Case 14 0.000(1.000) 0.000(1.000) -0.085(0.932) 0.969(0.333)
Control 13 -0.215(0.830) 2.366(0.018) 0.000(1.000) 0.031(0.975)
Mallon et al. (2006)
Case 14 NS NS NS NS
Control 17 NS NS NS NS
· Results are expressed as Test-statistic (p-value).
· NS indicates the original data do not need to conduct the symmetry test.
· p-value< 0.05 indicates the underlying data is not symmetric.
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Random effects model
Heterogeneity: I2 = 85%, τ2 = 0.7746, χ6
2
 = 40.01 (p < 0.01)
Bonnet et al. (2007)
Calmy et al. (2010)
Hurlimann et al. (2006)
Lo et al. (2015)
Stein et al. (2004)
Moyle et al. (2001)
Mallon et al. (2006)
Total
116
 12
 10
 29
 17
 20
 14
 14
Mean
6.063
5.489
6.614
5.140
5.580
7.500
7.600
SD
0.419
1.634
1.092
0.980
0.400
1.318
1.700
Case
Total
120
  9
 12
 29
 20
 20
 13
 17
Mean
−6.772
 5.454
 6.614
 4.970
 5.580
 7.364
 7.600
SD
1.399
1.342
1.092
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0.400
0.914
1.400
Control
−15 −10 −5 0 5 10 15
Standardised Mean
Difference SMD
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13.34
0.02
0.00
0.20
0.00
0.12
0.00
95%−CI
[−0.32;  1.17]
[ 9.21; 17.47]
[−0.82;  0.86]
[−0.51;  0.51]
[−0.45;  0.85]
[−0.62;  0.62]
[−0.64;  0.87]
[−0.71;  0.71]
Weight
100.0%
2.8%
15.2%
17.2%
16.4%
16.6%
15.7%
16.1%
Total Cholesterol: Statistics of each studies
(a) Total cholesterol
Study
Random effects model
Heterogeneity: I2 = 0%, τ2 = 0, χ7
2
 = 2.04 (p = 0.96)
Bonnet et al. (2007)
Calmy et al. (2010)
Eckard et al. (2014)
Ganesan et al. (2011)
Hurlimann et al. (2006)
Lo et al. (2015)
Stein et al. (2004)
Nakanjako et al. (2015)
Total
192
 12
 10
 67
 22
 29
 17
 20
 15
Mean
4.137
2.837
2.399
2.525
3.557
3.200
3.470
3.427
SD
0.755
0.774
0.614
0.452
1.092
0.950
0.320
2.208
Case
Total
196
  9
 12
 69
 22
 29
 20
 20
 15
Mean
4.160
3.354
2.542
2.525
3.557
3.230
3.470
4.646
SD
0.962
1.342
0.863
0.452
1.092
0.830
0.320
3.517
Control
−1 −0.5 0 0.5 1
Standardised Mean
Difference SMD
−0.13
−0.03
−0.46
−0.19
0.00
0.00
−0.03
0.00
−0.42
95%−CI
[−0.33; 0.07]
[−0.89; 0.84]
[−1.31; 0.39]
[−0.53; 0.15]
[−0.59; 0.59]
[−0.51; 0.51]
[−0.68; 0.61]
[−0.62; 0.62]
[−1.14; 0.31]
Weight
100.0%
5.3%
5.5%
35.1%
11.4%
15.1%
9.5%
10.4%
7.6%
LDL−C: Statistics of each studies
(b) LDL-C
Figure 9: Forest plots of effects in plasma concentrations of total cholesterol (9(a)), LDL-C
(9(b)) in HIV-infected patients.
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Random effects model
Heterogeneity: I2 = 0%, τ2 = 0, χ7
2
 = 0.73 (p = 1.00)
Bonnet et al. (2007)
Calmy et al. (2010)
Funderburg et al. (2015)
Lo et al. (2015)
Stein et al. (2004)
Nakanjako et al. (2015)
Moyle et al. (2001)
Mallon et al. (2006)
Total
174
 12
 10
 72
 17
 20
 15
 14
 14
Mean
0.937
1.074
1.228
1.340
0.940
1.700
0.936
1.100
SD
0.252
0.344
0.386
0.500
0.070
0.164
0.239
0.400
Case
Total
181
  9
 12
 75
 20
 20
 15
 13
 17
Mean
0.963
1.030
1.208
1.310
0.940
1.736
0.870
1.100
SD
0.262
0.327
0.386
0.390
0.070
0.409
0.249
0.400
Control
−1 −0.5 0 0.5 1
Standardised Mean
Difference SMD
0.04
−0.10
0.13
0.05
0.07
0.00
−0.12
0.27
0.00
95%−CI
[−0.17; 0.25]
[−0.97; 0.76]
[−0.71; 0.97]
[−0.27; 0.38]
[−0.58; 0.71]
[−0.62; 0.62]
[−0.83; 0.60]
[−0.49; 1.03]
[−0.71; 0.71]
Weight
100.0%
5.8%
6.2%
41.6%
10.4%
11.3%
8.5%
7.6%
8.7%
HDL−C: Statistics of each studies
(a) HDL-C
Study
Random effects model
Heterogeneity: I2 = 0%, τ2 = 0, χ7
2
 = 6.71 (p = 0.46)
Bonnet et al. (2007)
Calmy et al. (2010)
Hurlimann et al. (2006)
Lo et al. (2015)
Stein et al. (2004)
Nakanjako et al. (2015)
Moyle et al. (2001)
Mallon et al. (2006)
Total
131
 12
 10
 29
 17
 20
 15
 14
 14
Mean
2.147
4.048
3.036
1.609
3.780
1.709
4.484
3.800
SD
1.845
3.612
1.482
0.978
0.670
1.063
3.031
4.100
Case
Total
135
  9
 12
 29
 20
 20
 15
 13
 17
Mean
3.237
2.447
3.036
1.284
3.780
2.218
4.078
4.900
SD
2.012
1.677
1.482
0.391
0.670
1.472
3.131
7.800
Control
−1 −0.5 0 0.5 1
Standardised Mean
Difference SMD
0.01
−0.57
0.59
0.00
0.45
0.00
−0.40
0.13
−0.17
95%−CI
[−0.23; 0.26]
[−1.45; 0.31]
[−0.27; 1.44]
[−0.51; 0.51]
[−0.20; 1.11]
[−0.62; 0.62]
[−1.12; 0.33]
[−0.62; 0.89]
[−0.88; 0.54]
Weight
100.0%
7.6%
8.0%
22.2%
13.7%
15.3%
11.3%
10.3%
11.7%
Triglycerides: Statistics of each studies
(b) Triglycerides
Figure 10: Forest plots of effects in plasma concentrations of HDL-C (10(a)) and triglyc-
erides (10(b)) in HIV-infected patients.
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triglycerides) and, slight reduction in LDL-C level (SMD= −0.13 with 95% CI from -0.33
to 0.07). Note that the pooled conclusions we obtained are different from Banach et al.
(2016). In the original article, the authors concluded that there are significant reductions
in both total cholesterol and LDL-C levels. In contrast, we found that total cholesterol
level has a moderate growth trend and LDL-C level only has a slight reduction. As for
HDL-C and triglycerides levels, nearly zero pooled effect sizes declared that these two
plasma concentration levels do not have significant change in HIV-infected patients. The
opposite results we obtained indeed imply that it is essential to conduct a symmetry test
on the selected studies before estimating the sample mean and standard deviation. If the
included studies are blindly used to estimate the sample mean and standard deviation
without considering the symmetry of original data, it may increase computational error
and eventually lead to an inaccurate conclusion.
5.3 Case study of exploring the impact of statin therapy on
plasma MMP-3, MMP-9 and TIMP-I concentrations
In this section, we will discuss the third real case as introduced in Ferretti et al. (2017).
This data is a meta-analysis about whether statin therapy has influence on plasma MMP-
3, MMP-9 and TIMP-I concentration levels. Total 10 studies were selected to conduct
the systematic review. Note that in Ferretti et al. (2017), the authors compared the net
changes (mean difference) in measurements between pretreatment and posttreatment.
Since we tend to provide a demonstration for the usage of our proposed test statistics,
we will not compute the net changes as in Ferretti et al. (2017). Instead, the follow-up
measurements, i.e. posttreatment measurements are used to conduct the test and further
analysis. Note also that in the original data set, study Hanefeld et al. (2007) does not
record any information of the control set and hence, we will remove it from the following
analysis.
5.3.1 Data description
The basic information of the selected data is reported in Table 8. Similar to the previous
two cases, for plasma MMP-9, MMP-3 and TIMP-I levels, data were recorded as the
sample mean with standard deviation, or the sample median with interquartile range. As
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a result, test statistic T2 (Eq.(8)) will be used to test the symmetry of underlying data.
Likewise, if a study has p-value greater than 0.05, we regard it as appropriate to further
conduct the meta-analysis. If a study has p-value smaller than 0.05, it is recommended
to be excluded from further analysis.
Table 8: Summary of included studies in Ferretti et al. (2017)
Study
Sample
size
MMP-9
(ng/mL)
MMP-3
(ng/mL)
TIMP-I
(ng/mL)
Andrade et al. (2013)
Case 25 113±69 NS 281±231
Control 8 147±89 NS 354±287
Koh et al. (2002)
Case 32 28(19-34) 16±14 74±23
Control 31 26(17-41) 18±17 86±26
Mohebbi et al. (2014)
Case 21 164.95±126.68 NS NS
Control 21 180.81±115.93 NS NS
Singh et al. (2008)a
Case 23 10±6 NS NS
Control 24 2±6 NS NS
Singh et al. (2008)b
Case 22 9±6 NS NS
Control 24 2±6 NS NS
Broch et al. (2014)
Case 36 243(106-367) NS NS
Control 35 354(162-467) NS NS
Kalela et al. (2001)
Case 24 35.1±8.20 NS NS
Control 26 40.4±25.30 NS NS
Leu et al. (2005)
Case 32 0.39±0.22 NS NS
Control 19 0.42±0.22 NS NS
Nilsson et al. (2011)
Case 37 212(169-310) 21(16-28) 155(143-174)
Control 39 184(141-256) 20(14-24) 149(135-166)
· Observations are expressed as mean ± SD or median (interquartile range).
· NS indicates the information is not specified in the original study.
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5.3.2 Results of symmetry test and meta-analysis
The test results are provided in Table 9. Since in the original data set, only 3 studies
reported the sample median and interquartile range, Table 9 only report the test results
of these three studies. Fortunately, the reported data in all three studies had passed the
symmetry test (p-value greater than 0.05). That is, we can apply the methods provided
by Luo et al. (2017) and Wan et al. (2014) to estimate the sample mean and standard
deviation for these studies, respectively. Similar to the previous two cases, we generated
forest plots of overall effects from the statin therapy on patients’ plasma MMP-3, MMP-9
and TIMP-I concentrations (Figures 11(a), 11(b) and 11(c)).
Table 9: Results of symmetry test on reported data from Ferretti et al. (2017)
Study
Sample
size
MMP-9
(ng/mL)
MMP-3
(ng/mL)
TIMP-I
(ng/mL)
Koh et al. (2002)
Case 32 -0.795(0.427) NS NS
Control 31 0.976(0.329) NS NS
Broch et al. (2014)
Case 36 -0.211(0.833) NS NS
Control 35 -1.080(0.280) NS NS
Nilsson et al. (2011)
Case 37 1.677(0.094) 0.716(0.474) 0.971(0.332)
Control 39 1.115(0.265) -0.884(0.376) 0.428(0.669)
· Results are expressed as Test-statistic (p-value).
· NS indicates the original data do not need to conduct the symmetry test.
· p-value< 0.05 indicates the underlying data is not symmetric.
Similar to the previous two case studies, we only compute overall effect sizes of the
included data for demonstration purpose and will not conduct further analysis such as
sensitivity analysis. The effect sizes of each study and the overall results are shown in the
three graphs of Figure 11. Based on these three forest plots, the pooled results imply that
by using the statin therapy, patients’ plasma MMP-9 and MMP-3 levels at the end of
follow-up period may have a slightly increase (SMD= 0.15 with 95% CI from -0.25 to 0.56
for MMP-9 and SMD= 0.09 with 95% CI from -0.31 to 0.50 for MMP-3) than healthy
individuals. On the other hand, patients’ TIMP-I levels at the end of follow-up period
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may decrease very slightly (SMD= −0.13 with 95% CI from -0.68 to 0.42). Figure 11(a)
also indicates that there might be high heterogeneity among studies for MMP-9 levels
(Q = 35.41, I2 = 77% and p < 0.01). Note that in Figures 11(b) and 11(c), the values
of I2 imply that there are low or moderate heterogeneity among studies for MMP-3 and
TIMP-I levels, respectively (I2 = 32% for MMP-3 and I2 = 65% for TIMP-I). However,
the values of Q statistics for these two plasma levels are very small and p-values are
greater than 0.05 (Q = 1.46 with p = 0.23 for MMP-3; Q = 5.71 with p = 0.06 for TIMP-
I), which imply that both MMP-3 and TIMP-I levels hardly have heterogeneity among
selected studies. Such conflict conclusion about heterogeneity between studies may be
caused by the small number of studies included. As a result, if researchers aim to obtain
an accurate conclusion about the effects of statin therapy on patients’ plasma MMP-3
and TIMP-I levels, more studies and information are needed.
Based on the above three real data analysis, it is obvious that our proposed test
statistics are necessary for medical researchers, especially when we need to transform the
intermediate summary statistics (median, minimum, maximum or interquartile range)
to the sample mean and standard deviation. We believe by conducting the proposed
symmetry tests, researchers can efficiently find out and exclude the potential skewed data
to reduce the errors in computing the effect sizes.
6 Conclusion
Meta-analysis is a useful tool in evidenced-based medicine to statistically combine and an-
alyze clinical results from two or more independent trials. Researchers use different effect
size measurements to statistically compare the effectiveness of some particular medicine or
therapy. Mean difference based effect sizes are used to analyze continuous data in clinical
research. To compute the mean difference measurements, the sample mean and standard
deviation are two indispensable information. However, most of the medical studies do not
record these two statistics directly. Instead, the summary measurements such as the sam-
ple median, minimum and maximum or interquartile range are more likely to be reported.
In this case, researchers have to transform the reported data into the sample mean and
standard deviation. Our major concern is that even for the optimal estimation methods
of these two statistics (introduced by Luo et al. (2017) and Wan et al. (2014)), the es-
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Figure 11: Forest plots of effects in follow-up plasma MMP-9 (11(a)), MMP-3 (11(b)) and
TIMP-I (11(c)) concentration levels in patients that use statin therapy.
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timators are developed based on the symmetry assumption. Thus we recommend that
researchers should conduct a symmetry test for the underlying data before transform them
into the sample mean and standard deviation, in order to improve the accuracy of the
estimation. As a result, we introduce test statistics based on the summary measurements
for three most frequently appeared scenarios.
Table 10: Summary table of the test statistics under three scenarios
Test statistic Coefficient
Scenario S1 T1 = τ(n)(a+b−2m)b−a τ(n) = 2Φ−1
(
n−0.375
n+0.25
)/√
pi2
6 log(n) +
pi
n
Scenario S2 T2 = ϕ(n)(q1+q3−2m)q3−q1 ϕ(n) = 1.09
√
nΦ−1
(
0.75n−0.125
n+0.25
)
Scenario S3 T3 = κ(n)(a+b+q1+q3−4m)b−a+q3−q1 κ(n) =
[2Φ−1(n−0.375
n+0.25 )+2Φ−1(
0.75n−0.125
n+0.25 )]√
pi
2
6 log(n)+
10.5
n
For the three most popular scenarios, the corresponding test statistics and their coeffi-
cient functions are summarized in Table 10. All these three test statistics are theoretically
proved and have simple formulation which are easy for researchers to adopt in practice.
The simulation studies in Section 3 show that our proposed test statistics have statis-
tical power close to one and for both scenarios, which indicates that the test statistics
should have very good performance in detecting potential skewed data. Moreover, to
help researchers to make more convincing conclusions in medical research, we suggest a
proper path to conduct the meta-analysis in Figure 1 and the first step is to conduct the
symmetry test via our test statistics first. To further illustrate the usage of the newly
proposed test statistics, we applied them on three different real meta-analysis in Section
4. By conducting the symmetry test, the p-values show that some of the selected studies
of these three cases should be excluded before carry on to meta-analysis. As a result,
the results of meta-analysis with skewed data removed may be different from the orig-
inal conclusion. In particularly, for the case study about the effects of statin therapy
on plasma lipid concentrations in HIV-infected patients (Banach et al., 2016), compare
to the original article, we have opposite conclusion about the pooled effect sizes of total
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cholesterol level and LDL-C level. Since the simulation studies indicate the reliability
of the proposed test statistics, we expect that our test statistics and the recommended
procedure in Figure 1 can help researchers to obtain faithful conclusion in evidence-based
medicine.
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Appendix A: Some preliminary results
To derive the symmetry test for the three scenarios, we first present some preliminary
results for the normal distribution and for the associated order statistics. The normal
distribution N(µ, σ2) is commonly used in statistics for data analysis. Its probability
density function (pdf) is given as
φ(x|µ, σ2) = 1√
2piσ2
exp
{
−(x− µ)
2
2σ2
}
,
where µ is the mean value and σ2 is the variance, or equivalently, σ is the standard
deviation. For the normal distribution, µ is also known as the median and the mode.
When µ = 0 and σ2 = 1, the distribution reduces to the standard normal distribution
N(0, 1). Let also Φ(·) be the cumulative density function (cdf) of the standard normal
distribution. By symmetry, we have φ(z) = φ(−z) and Φ(z) = 1− Φ(−z).
To investigate the properties of the 5-number summary for the data, we introduce
some theoretical results for the order statistics Z(1) ≤ · · · ≤ Z(n) of the random sample
{Z1, . . . , Zn} from the standard normal distribution. By symmetry, Z(i) and −Z(n−i+1)
follow the same distribution, and (Z(i), Z(j)) and (Z(n−i+1), Z(n−j+1)) follow the same joint
distribution. According to Arnold and Balakrishnan (Arnold and Balakrishnan, 1989),
Chen (Chen, 2004) and Ahsanullah et al. (Ahsanullah et al., 2013), we have the following
two lemmas.
Lemma 1. Let Z1, . . . , Zn be a random sample of N(0, 1), and Z(1) ≤ · · · ≤ Z(n) be the
ordered statistics Z1, . . . , Zn. Then
E(Z(i)) = −E(Z(n−i+1)), 1 ≤ i ≤ n,
E(Z(i)Z(j)) = E(Z(n−i+1)Z(n−j+1)), 1 ≤ i ≤ j ≤ n.
Lemma 2. Let Z1, . . . , Zn be a random sample of N(0, 1), and Z([np]) be the pth quantile
of the sample, where [np] denotes the integer part of np. Let also Φ−1(·) be the inverse
function of Φ(·).
(i) For any 0 < p < 1, we have
√
n(Z([np]) − Φ−1(p)) d−→ N
(
0,
p(1− p)
[φ(Φ−1(p))]2
)
, as n→∞,
where
d−→ denotes convergence in distribution.
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(ii) For any 0 < p1 < p2 < 1, as n→∞, (Z([np1]), Z([np2])) follows asymptotically a bivari-
ate normal distribution with mean vector (Φ−1(p1),Φ
−1(p2)) and covariance matrix
Σ = (σij)2×2, where σ12 = σ21 and
σij =
pi(1− pj)
nφ(Φ−1(pi))φ(Φ−1(pj))
, 1 ≤ i ≤ j ≤ 2.
Lemma 3. Let Z1, . . . , Zn be a random sample of N(0, 1) and Z(1) ≤ Z(2) ≤ · · · ≤ Z(n)
be the corresponding order statistics. According to Theorem 14 in Ferguson (1996), the
sample maximum Z(n) has the following limiting distribution:√
2 log(n)Z(n) − 2 log(n) + 1
2
log(4pi log(n))→ Y,
where Y ∈ G3 = exp {−e−z}. By symmery, the sample minimum also has the following
limiting distribution:√
2 log(n)Z(2) + 2 log(n)− 1
2
log(4pi log(n))→ −W,
where W ∈ G3. By Theorem 15 in Ferguson (1996), the above two expressions converge
jointly as Y and W are independent. Hence, for the sample mid-range,
Z(1)+Z(n)
2
, satisfies,
√
2 log(n)
(
Z(1) + Z(n)
2
)
→ Y −W
2
.
where Y −W
2
follows the logistic distribution L(0, 1
2
).
Appendix B: Theoretical results of proposed test statistics
Recall that in Section 3.2, X1, . . . , Xn are defined as a random sample of size n from
the normal distribution N(µ, σ2), and X(1) ≤ · · · ≤ X(n) are the ordered statistics of
the sample. Meanwhile, they can represented as Xi = µ + σZi and X(i) = µ + σZ(i)
for i = 1, . . . , n. By the three lemmas in Appendix A, we have the following theoretical
results for the proposed estimators under the three scenarios, respectively.
Theorem 1. Under the null hypothesis, the test statistic T for scenario S1 can be further
written as
T0 =
a+ b− 2m
σ
√
pi2
6 log(n)
+ pi
n
,
where σ can be estimated by Eq. (3).
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Proof. Recall the test statistic T in (1), i.e.
T =
a+ b− 2m
SE(a+ b− 2m) .
By Lemma 3, we know that the sample mid-range for standard normal distributed
data,
(
Z(1) + Z(n)
)
/2, has variance Var
(
Z(1) + Z(n)
)
= pi2/ [6 log(n)] when n is large. By
Lemma 2, we can have the variance of the median for standard normal distributed data
is V ar(Z([0.5n])) =
pi
2n
, when n is large. Hence, under the assumption in Section 3.2, for
a = µ+ σZ(1), b = µ+ σZ(n) and m = µ+ σZ[0.5n], we have:
Var (a + b− 2m) = Var(a+ b) + 4Var(m)− 4Cov(a+ b,m)
≈ pi
2σ2
6 log(n)
+
2piσ2
n
− 4Cov(a+ b,m).
According to the simulation results of Cov(a+b,m), we found it very close to the variance
of the sample median, i.e. Var(m). Thus, we computed the ratio Cov(a + b,m)/Var(m)
and tended to use Var(m) to approximate the values of Cov(a + b,m). Based on the
simulation results, we figured out the ratio between these two terms is approximately
equal to 0.5. By plugging the this ratio between Cov(a + b,m) and Var(m) into the
previous formula of the variance, we can obtain the following equation:
Var (a+ b− 2m) ≈ pi
2σ2
6 log(n)
+
2piσ2
n
− 4
(
1
2
)(
piσ2
2n
)
=
pi2σ2
6 log(n)
+
piσ2
n
.
Recall the test statistic T in (1), the denominator SE (a+ b − 2m) =
√
Var (a + b − 2m), and
from the above derivation, by plugging in the above results into (1), we have,
T0 =
a+ b− 2m
σ
√
pi2
6 log(n)
+ pi
n
,
is the test statistic under the null hypothesis H0. Substituting σ in above equation by
(3), we can easily obtain the finalized test statistic (4)
Theorem 2. Under the null hypothesis, the test statistic T for scenario S2 can be further
written as
T0 =
√
n (q1 + q3 − 2m)
1.83σ
,
where σ can be estimated by Eq. (7).
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Proof. Recall the test statistic T in Eq. (5),
T =
q1 + q3 − 2m
SE(q1 + q3 − 2m)
According to the notations in Section 3.2, the sample first and third quartiles and
the median are represented by q1 = µ + σZ[0.25n], m = µ + σZ[0.5n] and q3 = µ +
σZ[0.75n]. By Lemma 1 and 2, when sample size n is large, we have Var(Z([0.25n])) =
0.25(0.75)
n[φ(Φ−1(0.25))]2
≈ 1.8568
n
, Var(Z([0.5n])) =
pi
2n
, Var(Z([0.75n])) ≈ 1.8568n , Cov(Z([0.25n]), Z[0.5n]) ≈
0.9860
n
, Cov(Z([0.25n]), Z([0.75n])) ≈ 0.6189n . Hence, we could easily obtain that
Var(q1) = Var(q3) ≈ 1.8568σ2/n, Var(m) = piσ2/2n,
Cov(q1, m) ≈ 0.9860σ2/n, Cov(q1, q3) ≈ 0.6189σ2/n.
As a result, under the null hypothesis H0, the test statistic T in (5) can be simplified
as
T0 =
q1 + q3 − 2m√
Var(q1 + q3)− 4Cov(q1 + q3, m) + 4Var(m)
=
q1 + q3 − 2m√
[2Var(q1) + 2Cov(q1, q3)]− 4[2Cov(q1, m)] + 4Var(m)
=
q1 + q3 − 2m√
σ2
n
[2(1.8568) + 2(0.6189)− 8(0.9860) + 2pi]
≈
√
n (q1 + q3 − 2m)
1.83σ
.
Use (7) to estimate the unknown parameter σ, we can obtain the finalized test statistic
as (8).
Theorem 3. Under the null hypothesis, the test statistic T scenario S3 can be further
written as
T0 =
a+ b+ q1 + q3 − 4m
σ
√
pi2
6 log(n)
+ 10.14
n
,
where σ can be estimated by Eq. (11).
Proof. Recall the test statistic T in (9), i.e.
T =
a+ b+ q1 + q3 − 4m
SE(a + b+ q1 + q3 − 4m) .
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By Lemma 1, we have for standard normal distribution, Var(Z([0.25n])) = Var(Z([0.75n])),
Cov(Z([0.25n]), Z([0.5n])) = Cov(Z([0.75n]), Z([0.5n])) and Cov(Z(1)+Z(n), Z([0.25n])) = Cov(Z(1)+Z(n), Z([0.75n])).
Also by Theorem 1, we can easily obtain that Cov(a+ b,m) ≈ 0.5Var(m) when n is large.
Similar as Theorem 1, by simulation, we found that the covariance term Cov(a + b, q1)
is very close to the variance of first quartile, i.e. Var(q1). As a result, we compute the
ratio between Cov(a+ b, q1) and Var(q1) to seek an approximation of Cov(a+ b, q1), with
respect to Var(q1). Eventually, we figured out that the ratio is approach to 0.45 as n
increases. Consequently, by plugging in the approximation equation of Cov(a+b, q1) and,
using Lemma 2 and 3,we have
Var(a+ b+ q1 + q3 − 4m) = Var(a+ b) + 2Var(q1) + 16Var(m)
+ 4Cov(a+ b, q1)− 8Cov(a+ b,m)− 16Cov(q1,m)
≈ Var(a+ b) + 2Var(q1) + 16Var(m)
+ 4(0.45)Var(q1)− 8(0.5)Var(m)− 16Cov(q1,m)
≈ pi
2σ2
6 log(n)
+
3.72σ2
n
+
8piσ2
n
+
3.348σ2
n
− 2piσ
2
n
− 15.78σ
2
n
≈ pi
2σ2
6 log(n)
+
7.068σ2
n
+
6piσ2
n
− 15.78σ
2
n
≈ pi
2σ2
6 log(n)
+
10.14σ2
n
Eventually, under the null hypothesis H0, the test statistic in (9) can be simplified as
T0 =
a+ b+ q1 + q3 − 4m
σ
√
pi2
6 log(n)
+ 10.14
n
.
After substitute the unknown parameter σ by the estimated σˆ in (11), we can obtain the
finalized test statistic T3 as in (12).
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